AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

2.480

-0.140-5.34%

Volume:2.46M

Turnover:6.11M

Market Cap:922.63M

PE:-8.79

High:2.600

Open:2.580

Low:2.440

Close:2.620

52wk High:5.870

52wk Low:1.800

Shares:372.03M

Float Shares:274.26M

Volume Ratio:1.43

T/O Rate:0.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.282

EPS(LYR):-0.201

ROE:-53.45%

ROA:-30.54%

PB:3.96

PE(LYR):-12.31

Loading ...

Overview Company News Filings

Clarity Pharmaceuticals H1 2026 Loss Worsening Challenges Bullish Profitability Narrative

Simply Wall St.

Clarity Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Income; Shares Jump 13%

MT Newswires Live

Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial

Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%

MT Newswires Live

Why Clarity Pharmaceuticals (ASX:CU6) Is Up 14.5% After Standout Phase II PSMA Imaging Results

Simply Wall St.

Clarity Pharmaceuticals (ASX:CU6) Valuation Check After New Co PSMA Abstract And Registrational Trial Progress

Simply Wall St.

Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial

Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CU6.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":2.48,"timestamp":1787292720000,"preClose":2.62,"halted":0,"volume":2460943,"delay":0,"changeRate":-0.05343511450381684,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.282253,"marketStatus":"Market Closed","change":-0.14,"latestTime":"08-21 16:12:00 AEST","open":2.58,"high":2.6,"low":2.44,"amount":6112772,"amplitude":0.061069,"askPrice":2.5,"askSize":3000,"bidPrice":2.47,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.282253,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.62,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.434727314908569,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":2.62,"auctionPrice":2.48,"auctionVolume":86670,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600774}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-30.54%","roe":"-53.45%","lyrEps":-0.201427,"volumeRatio":1.434727314908569,"shares":372030071,"dividePrice":0,"high":2.6,"amplitude":0.061069,"preClose":2.62,"low":2.44,"week52Low":1.8,"pbRate":"3.96","psRate":"87.21","week52High":5.87,"institutionHeld":0,"latestPrice":2.48,"committee":0.25,"eps":-0.282253,"divideRate":0,"volume":2460943,"delay":0,"ttmEps":-0.282253,"open":2.58,"prevYearClose":3.38,"prevWeekClose":2.63,"prevMonthClose":2.37,"prevQuarterClose":2.14,"fiveDayClose":2.63,"twentyDayClose":2.35,"sixtyDayClose":2.43,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616442038","title":"Clarity Pharmaceuticals H1 2026 Loss Worsening Challenges Bullish Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2616442038","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616442038?lang=en_us&edition=fundamental","pubTime":"2026-03-01 05:26","pubTimestamp":1772313967,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) has posted its H1 2026 scorecard, with investors watching how its revenue base and per share losses are tracking against ambitious growth expectations. The company has seen half year revenue move from A$6.1 million in H2 2024 to A$4.7 million in H1 2025 and A$4.8 million in H2 2025. Over the same periods, basic EPS moved from a loss of A$0.09 per share in H2 2024 to losses of A$0.07 in H1 2025 and A$0.13 in H2 2025. This sets the scene for a results season...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-h1-2026-loss-worsening-challenges-bu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-h1-2026-loss-worsening-challenges-bu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4112","BK7096","BLSG","BLSX","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614003067","title":"Clarity Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Income; Shares Jump 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614003067","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614003067?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:37","pubTimestamp":1772152660,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  reported Friday fiscal first-half loss of AU$0.153 per share, compared with a loss of AU$0.074 a year earlier.Analysts polled by FactSet expected loss of AU$0.08.Income for the six months ended Dec. 31, 2025, was AU$10 million, compared with AU$10.9 million a year earlier.The company did not generate revenue from external customers for the period since it is in the development stage and has no commercial products.Shares of the company rose 13% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613787730","title":"Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2613787730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613787730?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:02","pubTimestamp":1771855322,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals reported an update from the Phase II cohort expansion of its SECuRE trial  evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL50jZBy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613084422","title":"Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613084422","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613084422?lang=en_us&edition=fundamental","pubTime":"2026-02-23 10:20","pubTimestamp":1771813245,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  said a participant with metastatic castration-resistant prostate cancer in the phase 2 group expansion phase of the SECuRE trial achieved undetectable disease as assessed by prostate-specific antigen and prostate-specific membrane antigen positron emission tomography, according to a Monday Australian bourse filing.The trial is evaluating the safety and efficacy of the company's targeted copper therapy-diagnostic product, copper-67-SAR-bisPSMA, for the potential treatment of prostate cancer.The participant achieved undetectable prostate-specific antigen levels seven weeks after his first cycle of copper-67-SAR-bisPSMA, the filing said. No disease was observed on prostate-specific membrane antigen positron emission tomography after receiving one more cycle of copper-67-SAR-bisPSMA. The participant showed mild related adverse effects, including altered taste, dry eyes, eye pain, fatigue, and salivary gland soreness. No blood-related or renal adverse effects were o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COPJ","BK4535","BK7096","CPXR","MHGmain","CPER","CU6.AU","QCmain","XME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612940145","title":"Why Clarity Pharmaceuticals (ASX:CU6) Is Up 14.5% After Standout Phase II PSMA Imaging Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2612940145","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612940145?lang=en_us&edition=fundamental","pubTime":"2026-02-19 17:28","pubTimestamp":1771493310,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals recently announced that an abstract from its Co-PSMA Phase II investigator-initiated trial of 64Cu-SAR-bisPSMA has been accepted for oral presentation at the EAU Congress 2026, highlighting data from multiple studies including COBRA, PROPELLER and SECuRE.\nThe trial results indicated that 64Cu-SAR-bisPSMA more than doubled the number of prostate cancer lesions detected per patient versus standard-of-care imaging, with management plans altered in 44% of participants...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/why-clarity-pharmaceuticals-asxcu6-is-up-145-after-standout","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/why-clarity-pharmaceuticals-asxcu6-is-up-145-after-standout","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4543","CU6.AU","BK4587","BK4551","BK4528","BK4585","BK7096","BK4588","BK4023","AI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612663774","title":"Clarity Pharmaceuticals (ASX:CU6) Valuation Check After New Co PSMA Abstract And Registrational Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2612663774","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612663774?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:14","pubTimestamp":1771334043,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) is back in focus after announcing that an abstract on its dual targeting Co-PSMA agent has been accepted for oral presentation at the EAU Congress 2026, highlighting progress across multiple prostate cancer imaging trials.\nSee our latest analysis for Clarity Pharmaceuticals.\nThe EAU abstract sits alongside a strong run of short term momentum, with a 7 day share price return of 9.48% and a 30 day share price return of 7.83%. However, the year to date share...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-asxcu6-valuation-check-after-new-co","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-asxcu6-valuation-check-after-new-co","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","CU6.AU","LU2065732104.USD","BK4097","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611748526","title":"Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611748526","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611748526?lang=en_us&edition=fundamental","pubTime":"2026-02-16 22:03","pubTimestamp":1771250600,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd. announced that data from the Co-PSMA Investigator-Initiated Trial , evaluating its diagnostic product 64Cu-SAR-bisPSMA in comparison to standard-of-care 68Ga-PSMA-11, will be presented at the European Association of Urology  Congress 2026. The study was conducted in 50 patients with biochemical recurrence of prostate cancer following radical prostatectomy. According to the released abstract, 64Cu-SAR-bisPSMA more than doubled prostate cancer lesion and patient detection rates compared to 68Ga-PSMA-11. Further data will be outlined following the oral presentation at EAU 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDL9Bks3h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611170618","title":"Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611170618","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611170618?lang=en_us&edition=fundamental","pubTime":"2026-02-16 11:12","pubTimestamp":1771211535,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  said that its copper-64-SAR-bisPSMA diagnostic candidate identified a \"statistically significant\" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography /computed tomography  in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.At a per-patient level, gallium-68-PSMA-11 identified 36% of trial par","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XME","CPER","MHGmain","BK7096","CU6.AU","QCmain","COPJ","BK7047","PET.AU","BK4535","CPXR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":48,"code":"91000000","status":"200"}]}}